Significant Developments: Innovent Biologics (01801) has entered into a global strategic collaboration with Pfizer to accelerate the development of innovative oncology drugs. Henlius (02696) has received approval in mainland China for the market launch of its independently developed HANBEIYOU. DongRui Pharmaceutical (02348) has obtained drug production registration approvals for its 50mg and 100mg trazodone hydrochloride tablets. CSPC Pharmaceutical (01093) announced that Enituo® (anlotinib hydrochloride injection) has been approved for market launch by the National Medical Products Administration. Sino Biopharmaceutical (01177) has received approval for the market launch of naldemedine, a peripheral μ-opioid receptor antagonist. PATEO (02889) held a strategic cooperation signing ceremony and related exchange activities with NVIDIA in the United States. MINIEYE (02431) plans to acquire a 50% equity stake in Xi'an Tongtu Technology for RMB 25 million to bolster its smart logistics and autonomous driving capabilities. ITC PROPERTIES (00199) has made significant progress in its artificial intelligence computing power business, signing its first AI computing power technical service contract and entering into a strategic cooperation framework agreement with Ronglian Technology (002642.SZ). 5100 XIZANG (01115) has obtained Halal certification from Malaysia for several of its water products, marking a milestone in its overseas strategic expansion. DEEP SOURCE (00990) has entered into an agreement to purchase and process 150,000 tonnes of spodumene concentrate, supporting the implementation of its AI infrastructure-related business. Jingtai Holdings (02228) has achieved two breakthrough advancements: one in self-developed innovative peptide food ingredients and another in the innovative drug pipeline of an incubated enterprise. YIDU TECH (02158) intends to acquire a company primarily engaged in the operation of an online physician platform and related services for RMB 400 million. Green Technology International (00195) received a partial tender offer from Highpower Environment (Hong Kong) Investment to acquire up to 220 million shares at a discount of approximately 10.71%.
Operational Performance: China Power (02380) reported a total consolidated electricity sales volume of 10.6934 million MWh for April, representing a year-on-year increase of 4.80%. Grand Group (01991) released its 2025 annual results, showing revenue of HKD 758 million. Trading of its shares will resume on June 1st.
Comments